Hansa Biopharma AB (STU:24H) FFO


STU:24H Hansa Biopharma AB STU:24H
49 GF Score
Price €3.19
GF Value €2.20
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB FFO?

FFO (Funds from operations) only applies to REITs.

STU:24H
49GF Score
Hansa Biopharma AB STU:24H
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hansa Biopharma AB (STU:24H) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of €3.19 is trading 45% above its estimated GF Value™ of €2.20.

Key valuation signals for STU:24H:

  • FFO:
  • GF Value™: €2.20 vs. price of €3.19 (45% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the STU:24H stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score

Get the complete analysis for STU:24H

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.19
Price
€2.20
GF Value